Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$1.71 USD
-0.06 (-3.12%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $1.74 +0.03 (1.75%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RPTX 1.71 -0.06(-3.12%)
Will RPTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPTX
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue Estimates
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Repare Therapeutics (RPTX) a New Buy Stock
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for RPTX
1,2,3 Pullback Bullish appears for RPTX after 3.12% move
Technical picture remains unchanged for RPTX after it rises 1.44% on September 19
Sideways movement on September 17 results in no shift to RPTX’s technical outlook
RPTX's price falls by 1.42% on September 16, though its technical setup remains stable.
NR7 appears for RPTX after 0.28% move